Concepedia
Publication | Open Access
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
286
Citations
21
References
2021
Year
Page 1